Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 7/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 7/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 0.57 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 0.57 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3491077 | 0.99 | HDAC3 (0.56) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL12030815 | 0.95 | HDAC3 (0.60) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL537621 | 0.89 | HDAC3 (0.57) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Hydrochloric Acid SCHEMBL537822 | 0.87 | HDAC8 (0.56) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL6561130 | 0.87 | KDM4E (0.68) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL620087 | 0.87 | KDM4E (0.64) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Hydrochloric Acid SCHEMBL4265245 | 0.86 | HDAC8 (0.55) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL23957160 | 0.85 | HDAC3 (0.55) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL6560495 | 0.85 | KDM4E (0.69) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL30094698 | 0.85 | HDAC3 (0.55) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115403579-A | Novel spiro derivative and application thereof | 上海拓界生物医药科技有限公司 | 2022-11-29 | — | — | CN | disclosed |
| US-20210330650-A1 | SPIROCHROMANE DERIVATIVES | RICHTER GEDEON NYRT. (HU) | 2021-10-28 | — | — | US | disclosed |
| US-10385070-B2 | Chroman-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-20 | — | — | US | disclosed |
| EP-2675812-B1 | CHROMAN - SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2017-08-30 | — | — | EP | disclosed |
| EP-2675812-A1 | CHROMAN - SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2013-12-25 | — | — | EP | disclosed |
| US-20120245136-A1 | CHROMAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-09-27 | — | — | US | disclosed |
| WO-2012112743-A1 | CHROMAN - SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-23 | — | — | WO | disclosed |
| US-20110166124-A1 | TRICYCLIC SPIROCYCLE DERIVATIVES AND METHODS OF USE | MCCORMICK KEVIN D | 2011-07-07 | — | — | US | disclosed |
| US-20110166124-A1 | TRICYCLIC SPIROCYCLE DERIVATIVES AND METHODS OF USE | MCCORMICK KEVIN D | 2011-07-07 | — | — | US | disclosed |
| WO-2010027567-A2 | TRICYCLIC SPIROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2010-03-11 | — | — | WO | disclosed |
| WO-2004058727-A1 | SUBSTITUTED 3,5-DIHYDRO-4H-IMIDAZOL-4-ONES FOR THE TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245136-A1 | CHROMAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, KCNJ1, KCNC1 | HDAC3 170/4885HDAC4 238/4885HDAC1 257/4885 |
| US-20210330650-A1 | SPIROCHROMANE DERIVATIVES | CHRNA7, CHRM3, ADRB3 | HDAC3 120/4885HDAC4 914/4885HDAC1 313/4885 |
| US-10385070-B2 | Chroman-spirocyclic piperidine amides as modulators of ion channels | KCNJ2, KCNJ1, KCNC1 | HDAC3 170/4885HDAC4 238/4885HDAC1 257/4885 |
| US-20110166124-A1 | TRICYCLIC SPIROCYCLE DERIVATIVES AND METHODS OF USE | GPR119, TRPV1, NR3C2 | HDAC3 62/4885HDAC4 348/4885HDAC1 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.